Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John L Gerin

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Intervirology|February 5, 2003
Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infectionStephan Menne, Carol A Roneker, Bud C Tennant, et al.
Journal of Virology|May 7, 2002
Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infectionStephan Menne, Carol A Roneker, Brent E Korba, et al.
Antiviral Chemistry & Chemotherapy|November 27, 2002
Viral pharmacodynamic model for (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine) in chronically infected woodchucksSelwyn J Hurwitz, Bud C Tennant, Brent E Korba, et al.
Journal of Medical Virology|August 22, 2009
Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome-DNA complexes as adjuvantPaul J Cote, Scott D Butler, Andrea L George, et al.
Antiviral Research|August 11, 2004
Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus modelJames R Jacob, Brent E Korba, Paul J Cote, et al.
Antiviral Research|June 22, 2002
Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudineKathleen M Tatti, Brent E Korba, Heather L Stang, et al.
Antiviral Therapy|January 18, 2005
Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infectionBrent E Korba, Paul J Cote, Stephan Menne, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2005
Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucksJohn Casey, Paul J Cote, Illia A Toshkov, et al.
Antimicrobial Agents and Chemotherapy|August 5, 2008
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infectionStephan Menne, Scott D Butler, Andrea L George, et al.
Hepatology (Baltimore, Md.)|April 2, 2004
Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumorsJames R Jacob, Agnes Sterczer, Ilia A Toshkov, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Intervirology|February 5, 2003
Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infectionStephan Menne, Carol A Roneker, Bud C Tennant, et al.
Journal of Virology|May 7, 2002
Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infectionStephan Menne, Carol A Roneker, Brent E Korba, et al.
Antiviral Chemistry & Chemotherapy|November 27, 2002
Viral pharmacodynamic model for (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine) in chronically infected woodchucksSelwyn J Hurwitz, Bud C Tennant, Brent E Korba, et al.
Journal of Medical Virology|August 22, 2009
Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome-DNA complexes as adjuvantPaul J Cote, Scott D Butler, Andrea L George, et al.
Antiviral Research|August 11, 2004
Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus modelJames R Jacob, Brent E Korba, Paul J Cote, et al.
Antiviral Research|June 22, 2002
Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudineKathleen M Tatti, Brent E Korba, Heather L Stang, et al.
Antiviral Therapy|January 18, 2005
Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infectionBrent E Korba, Paul J Cote, Stephan Menne, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2005
Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucksJohn Casey, Paul J Cote, Illia A Toshkov, et al.
Antimicrobial Agents and Chemotherapy|August 5, 2008
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infectionStephan Menne, Scott D Butler, Andrea L George, et al.
Hepatology (Baltimore, Md.)|April 2, 2004
Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumorsJames R Jacob, Agnes Sterczer, Ilia A Toshkov, et al.
Pageof 3